Nobuo Koinuma

Health related quality of life in Japanese men after radical prostatectomy or radiation therapy for localized prostate cancer

Abstract  Background:  We performed a retrospective survey of general and disease specific health‐related quality of life (HRQOL) after radical prostatectomy (RP) and external beam radiotherapy (XRT) in Japanese men.

Recovery of health related quality of life after radical prostatectomy in Japanese men: A longitudinal study

Abstract Background: We performed a longitudinal survey of health related quality of life (HRQOL) after radical retropubic prostatectomy (RP) in Japanese men with localized prostate cancer.

The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis

We constructed a mathematical model for assessing the cost-effectiveness of providing BMD (bone mineral density) scans to Japanese women aged 55 years and over and treating, with risedronate, those that are shown to be osteoporotic. Fracture rates, cost data, utility values, and the increased risks of fractures associated with T-score and vertebral fracture history were taken from published literature. We estimated the cost of fractures avoided due to risedronate treatment, allowing the net changes in cost, incorporating both intervention and fracture costs to be calculated. The QALYs (quality adjusted life years) gained through treatment were calculated enabling cost per QALY ratios to be presented. Further analyses were undertaken assuming treatment was reserved for older women and/or those who had sustained a vertebral fracture in the previous 2 years. Cost per QALY values were inversely related to absolute risk of fracture. Assuming a cost per QALY value threshold of US

Health‐related quality of life after radical prostatectomy in Japanese men with localized prostate cancer

100,000, we concluded that providing BMD scans to women aged 70 years and over who had sustained a vertebral fracture in the previous 2 years and treating those that were osteoporotic was cost-effective. However, providing BMD scans for women without a vertebral fracture in the previous 2 years was not cost-effective, even in women aged 85 years and older.

Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.

Purpose:  We evaluated retrospectively health‐related quality of life (HRQOL) after radical prostatectomy (RP) in Japanese men with localized prostate cancer.

Proposal for the Breakdown of Increased Cancer Healthcare Cost and Its Improvement

Background: We investigated the changes in health‐related quality of life (HRQOL) in patients who underwent prostatectomy (RP) with or without neoadjuvant hormonal therapy (NHT).

Abstract A05: Economic benefit of Helicobacter pylori screening and eradication treatment for the prevention of gastric cancer

Technological progress in the field of cancer treatment can be expected to accelerate in the future, giving hope to such patients. At the same time, there is concern that cancer care will become more expensive. It is indispensable to minimize the economic burden of patients to deliver technological advances in treatment. It is important for the physician engaged in cancer care to recognize the economic burden of patients and to reduce this burden as much as possible. The Cancer Control Act was enacted in 2007 to promote work on cancer control using all the resources of the nation, and this should surely entail financial support. In order to take advantage of innovations in cancer care, reform of the payment system to lighten the economic burden of the patient would be a pressing necessity.

Abstract B37: Genetic screening of HNPCC

Background: The association between Helicobacter pylori infection and gastric cancer, which remains a major health problem in Japan, is well established. Detecting infected persons by simple testing and administering eradication treatment might be an effective means to prevent gastric cancer. However, when considering mass screening, the economic benefit must be proven. The purpose of this study is to predict the economic benefit of an H. pylori eradication strategy as a method to prevent of gastric cancer. Methods: Using data in the literature and demographic statistics, the number of persons infected with H. pylori, the infection rate, and the number of those who developed gastric cancer by H. pylori were estimated. Then, a cost benefit analysis of H. pylori screening and eradication treatment was done by using data from the patient survey, basic survey on wage structure, and list of medical fees. The costs are those of screening and eradication treatment, and the benefits are fees that would otherwise have been used for the treatment of gastric cancer, time lost that would have been from work, and the economic loss due to premature death caused by gastric cancer. Results: The infection rates at 10-19, 40-49 and 60-69 years of age were 2.5%, 28.1% and 52.6%, respectively for the year 2010, and the total number of infected persons was estimated to be 37.3 million (29.1% of the whole population). The number of persons who would be at risk of gastric cancer during their lives due to H. pylori infection was 750,000 when we assumed 2% as the risk of gastric cancer by H. pylori infection. The numbers of infected people in 2020, 2030 and 2050 were projected to be 31.3 million, 24.5 million and 11.0 million, respectively. The numbers of persons who would be at risk of gastric cancer due to the H. pylori infection in 2020, 2030 and 2050 would be 630,000, 490,000 and 220,000, respectively. When the subjects of screening and eradication treatment are assumed to be from 16 to 39 years old, and when the response rates of screening and eradication treatment are set at 30% and 60%, respectively, the cost in 2010 would be

Strategies for Improving Pediatric Services in Japan

841 million. In the case of 20% and 40%, the cost would be

A new modified catheter for voiding cystourethrography.

469 million. In the case of 40% and 70%, it would be